Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Depreciation & Amortization (CF) of $2.0 million for Q1 2026, down 1.27% year-over-year from $2.0 million in Q1 2025, and little changed quarter-over-quarter from $2.0 million in Q4 2025.
Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Depreciation & Amortization (CF) for 8 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 1.27% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.3 million (up 4.11% YoY), while the FY2025 annual figure was $8.3 million, up 12.75% from the prior year.
- Depreciation & Amortization (CF) steadied at $2.0 million in Q1 2026 per KYMR's latest filing, from $2.0 million in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q3 2025 and bottomed at $687000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $1.4 million across 5 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) soared 123.01% — and 2026, when it retreated 1.27%.
- Kymera Therapeutics' Depreciation & Amortization (CF) stood at $818000.0 in 2022, then climbed by 8.92% to $891000.0 in 2023, then jumped by 123.01% to $2.0 million in 2024, then increased by 2.26% to $2.0 million in 2025, then dropped by 0.49% to $2.0 million in 2026.
- Business Quant data shows KYMR's Depreciation & Amortization (CF) at $2.0 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.10 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 40.52 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 3.18 Mn |
| 10 | Kymera Therapeutics | 9.72 Bn | 9.03 Bn | - | 2.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.03 Mn |
| Jun 30, 2026 | 2.03 Mn |
| Mar 31, 2026 | 2.02 Mn |
| Mar 31, 2026 | 2.02 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Dec 31, 2025 | 2.03 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Sep 30, 2025 | 2.15 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Jun 30, 2025 | 2.08 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.46 Mn |
| Mar 31, 2024 | 1.46 Mn |